InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
Monksdream PremiumMember
01/14/24 2:02 PM
profile icon
Monksdream PremiumMember
09/13/23 1:57 PM
profile icon
subslover PremiumMember
06/16/22 5:44 PM
profile icon
Pedro2004 Free
06/16/22 1:00 PM
profile icon
subslover PremiumMember
06/16/22 11:54 AM
profile icon
Pedro2004 Free
06/16/22 10:47 AM
profile icon
Pedro2004 Free
06/15/22 10:00 AM
profile icon
Pedro2004 Free
06/15/22 9:21 AM
profile icon
PennyPusher786 PremiumMember
06/15/22 9:16 AM
profile icon
Pedro2004 Free
06/15/22 9:06 AM
profile icon
subslover PremiumMember
06/15/22 8:37 AM
profile icon
Runners123 Free
04/29/22 11:08 AM
profile icon
JJL Free
04/28/22 5:26 PM
profile icon
europtiger Free
04/28/22 2:24 PM
profile icon
Hercules1 PremiumMember
04/28/22 9:25 AM
profile icon
Hercules1 PremiumMember
04/28/22 9:23 AM
profile icon
THEMASTERS_SON Free
04/27/22 8:28 PM
profile icon
THEMASTERS_SON Free
04/27/22 4:20 PM
profile icon
Hercules1 PremiumMember
04/27/22 2:49 PM
profile icon
THEMASTERS_SON Free
04/27/22 11:09 AM
profile icon
Hercules1 PremiumMember
04/27/22 10:44 AM
profile icon
THEMASTERS_SON Free
04/27/22 6:23 AM
profile icon
THEMASTERS_SON Free
04/27/22 6:03 AM
profile icon
saigai Free
04/26/22 6:03 PM
profile icon
THEMASTERS_SON Free
04/26/22 5:34 PM
profile icon
THEMASTERS_SON Free
04/26/22 5:32 PM
profile icon
saigai Free
04/26/22 12:24 PM
profile icon
Hercules1 PremiumMember
04/26/22 11:45 AM
profile icon
Imarket13 Free
04/26/22 10:57 AM
profile icon
Hercules1 PremiumMember
04/26/22 10:54 AM
profile icon
THEMASTERS_SON Free
04/26/22 10:51 AM
profile icon
Hercules1 PremiumMember
04/26/22 10:51 AM
profile icon
THEMASTERS_SON Free
04/26/22 10:41 AM
profile icon
Imarket13 Free
04/26/22 10:16 AM
profile icon
saigai Free
04/26/22 10:07 AM
profile icon
Hercules1 PremiumMember
04/26/22 9:58 AM
profile icon
Awl416 Free
04/26/22 8:46 AM
profile icon
Awl416 Free
04/26/22 8:30 AM
profile icon
Cuppy Free
03/21/22 8:39 AM
profile icon
Adw20mri Free
01/12/22 1:33 PM
profile icon
fishhunter Free
08/13/21 4:11 PM
profile icon
ThatHawaiiGuy Grandfathered
04/06/21 7:10 PM
profile icon
shalley Free
03/23/21 11:13 AM
profile icon
fishhunter Free
03/23/21 10:29 AM
profile icon
shalley Free
03/18/21 11:55 AM

Evoke Pharma Inc. (EVOK) RSS Feed

Followers
55
Posters
212
Posts (Today)
0
Posts (Total)
1738
Created
10/30/13
Type
Free
Moderators
CHEAPEST FDA Play with MASSIVE upside potential .stock is still under radar but this will change once they resubmit the NDA in this Quarter .

MEGA Drug targeting a $3+ BILLION Market is close to NDA-Resubmission expected before year end with potential FDA approval in Q2 .Market cap of $21 million is a PURE GIFT , this low float stock could run to $4+ even BEFORE FDA Decision . Now is the perfect time to load up before the news about NDA resubmission hit the wire which likely will attract more new investors .GL


Evoke Pharma (EVOK)

Market-Cap: $21 Million
Cash: $6.5 Million (additional ~$5 million available via ATM)
Price: $0.87

Shares Out: 24.1 Million


Presentation
https://evokepharmainc.gcs-web.com/static-files/0f21016a-d472-4005-a293-dd8d02a857e7


•Gimoti™: Novel nasal delivery of metoclopramide for the symptomatic relief of acute and recurrent diabetic gastroparesis in women

•Large market opportunity:~12-16M patients with symptoms (80% women); ~2-3M currently treated in US given limited efficacy from few available treatment options

•Only one FDA-approved therapy for gastroparesis: Metoclopramide (oral & IV) still has ~4M prescriptions of the oral medication prescribed annually

•Positive data from pivotal comparative exposure PK study: Gimoti demonstrated AUC equivalence

•Estimated $3-4B prescription market

•Resubmission of 505(b)(2) NDA expected Q4 2019

If approved, Gimoti would be the first non-oral pharmacotherapy for gastroparesis approved in 40 years; metoclopramide is currently available in oral and injectable formulations.




Evoke Pharma Signs Commercial and Financial Agreement for its Lead Product Gimoti™ in the U.S. with Novos Growth Partners
https://www.globenewswire.com/news-release/2019/01/07/1681258/0/en/Evoke-Pharma-Signs-Commercial-and-Financial-Agreement-for-its-Lead-Product-Gimoti-in-the-U-S-with-Novos-Growth-Partners.html


Largest Shareholders

Latterell ...2.1M
Michigan ...400.0K
Garner (Cam L) ...335.6K
Gonyer (David A) ...319.5K
D’Onofrio ...238.8K
The Vanguard ...224.8K
Geode Capital ...107.4K
Creative ...100.0K
Virtu Americas LLC ...70.3K
Citadel LLC ...59.0K




Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
New Post